Asterias Biotherapeutics — ASCO 2015
13 slides from Asterias Biotherapeutics's conference presentation, Jun 9, 2015
Slide 1: Long-term Follow-up of Patients with AML Receiving an Autologous Telomerase-based Dendritic Cell Vaccine
ASCO May 30, 2015 1 Long-term Follow-up of Patients with Acute Myelogenous Leukemia Receiving an Autologous Telomerase-based Dendritic Cell VaccineH. Jean Khoury, MD, FACP, Robert H. Collins Jr., MD, William Blum, MD, Patrick Stiff, MD, Jane S Lebkowski, PhD, Edward Wirth III, MD PhD, Kevin Nishimot
Slide 2: AST-VAC1: Autologous Dendritic Cells Pulsed with hTERT mRNA
AST-VAC1: Autologous Dendritic Cells Pulsed with hTERT mRNA 2 Dendritic Cells: Potent Antigen Presenting Cells Telomerase: “Universal” Tumor Antigen Objective: Stimulate Anti-Tumor Immune Responses in Patients with AML AST-VAC1 is an immunotherapeutic product that comprises mature DC transfected wit
Slide 3: AST-VAC1 Production
AST-VAC1 Production 3 Leukapheresis Harvest Immature Dendritic Cells Differentiation LAMP hTERT mRNA ImmatureDendritic Cells DC Maturation MatureDendritic Cells Monocyte Enriched PBMCs CryopreservedAutologous DC Vaccine Product Release Based on: Demonstration of positive hTERT transfection Mature De
Slide 4: AML Clinical Trial Design and Study Schema
18 years or older AML with intermediate or high risk cytogenetics in CR1 within 6 months from induction chemotherapy and may or may not have received consolidation including autologous stem cell transplantationAML in CR2 with a CR1 of > 6 months durationExclusion: AML with t(15;17), t(8;-21), inv(16
Slide 5: Patient Demographics and Disease Status
Patient Demographics and Disease Status 5 Total Patients: N=33 Age (years) Median 61.2 Mean (SD) 58.3 (11.79) Min, Max 30.5, 75.4 Sex Male 17 (51.5%) Female 16 (48.5%) Race American Indian or Alaska Native 0 Asian 0 Black or African American 5 (15.2%) Native Hawaiian or Other Pacific Islander 0 Whit
Slide 6: AST-VAC1: Manufacturing Review and Disposition to Patients
AST-VAC1: Manufacturing Review and Disposition to Patients 6 24 Patients Had Successful AST-VAC1 Production Campaigns 24 Patients Reassessed for Eligibility 3 Patients Florid Relapse Prior to Vaccination 2 Patients in Early Relapse at Time of Vaccination 21 Patients Received at Least 3 Vaccinations
Slide 7: AST-VAC1 in AML: Excellent Safety Profile
AST-VAC1 in AML: Excellent Safety Profile 7 21 Total Patients Received AST-VAC116 CR1 3 CR2 2 Early Relapse Safety and TolerabilityDuring Leukapheresis:No Grade 3-4 Adverse EventsDuring Vaccination Period:Serious Adverse Events Grade 3-4 (2)Possibly Related: Idiopathic thrombocytopenic purpura (1 da
Slide 8: AST-VAC1 in AML: DTH and hTERT Specific T Cell Responses
AST-VAC1 in AML: DTH and hTERT Specific T Cell Responses 8 19 Total Patients in CR At Time of AST-VAC1 Administration16 CR1 3 CR2 11 of the 19 AML patients in CR developed cell immune responses to telomerase DTH responses hTERT specificT cell responses 11 of the 19 AML patients in CR developed DTH r
Slide 9: Kinetics of Development of Detectable hTERT Specific T Cell Responses
AST-VAC1 in AML: Kinetics of Development of Detectable hTERT Specific T Cell Responses 9 ID Age Status at Start of Vaccination Detection of Positive hTERT Specific T cell Responses Timepoints Post Vaccination Any Timepoint Primary Vaccinations Rest Boost Vaccinations 1641 33 CR1 + + - + 2141 37 CR1
Slide 10: Long-term Relapse Status: Greater Than 50% of Patients Relapse-free
Long-term Relapse Status: Greater Than 50% Of Patients Relapse-free (median 52 +/- 17 months) 10 Long-term Follow-up (2013-2014) % Patients Relapse-free*** Median (Range) Follow-up(mos) Relapse-free Patients with hTERT specific T cell responses All Patients in CR 11/19*(58%) 52 (13-59) 7/11(64%) Pat
Slide 11: Relapse Free-Survival and hTERT-Immune Response
Relapse Free-Survival and hTERT-Immune Response 11 Relapse Post-Hoc Analysis Shows Potential Trend that hTERT-specific T Cell Responses Associated with Longer Relapse-free SurvivalRequires Confirmation in Additional Trials
Slide 12: Summary
Summary 12 AST-VAC1 Produced for 73% of Patients Enrolled in TrialMean 17.2 Doses AST-VAC1 Delivered per Patient11/19 developed hTERT Specific T cell Responses58% Relapse-free median 52 mos follow-up.4/7 patients >60 years old relapse–free median 54 mos follow-upFavorable Survival Compared to Histor
Slide 13: Acknowledgements
Acknowledgements 13 Clinical Investigators and Staff: • Emory University: Martha Arellano, Edumund Waller, Mersiha Torlak, Susan Sunay, Ellie Hamilton • Washington University: Camille Abboud, Elizabeth Procknow, Jeremy Gabriel, Mary Kay Belota • Ohio State University: Anders Lindquist, Lynn O’Donnel